Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease [0.03%]
DS8201用于HR阳性、HER2低表达/超低表达的晚期乳腺癌（DESTINY-Breast06）：先前一线内分泌治疗±CDK4/6抑制剂进展时间及基线疾病负担的预设探索性分析
G Curigliano,X Hu,R Dent et al.
G Curigliano et al.
Background: In DESTINY-Breast06, trastuzumab deruxtecan (T-DXd) improved progression-free survival (PFS) versus physician's choice of chemotherapy (TPC) for patients with hormone receptor-positive (HR+), HER2-low/-ultralo...
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD [0.03%]
奥希替尼联合datopotamab deruxtecan治疗一线奥希替尼经治进展的EGFR突变型晚期NSCLC患者：ORCHARD研究
J W Riess,H A Yu,X Le et al.
J W Riess et al.
Background: ORCHARD (NCT03944772) was a phase II platform study conducted to characterize resistance mechanisms and evaluate novel treatment combinations following progressive disease (PD) on first-line osimertinib. Datop...
Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer [0.03%]
ENZALUTAMIDE联合镭-223治疗转移性去势抵抗性前列腺癌的最终总生存结果：EORTC 1333/PEACE-3试验
S Gillessen,E Gallardo,A Choudhury et al.
S Gillessen et al.
Background: The primary analysis of the EORTC 1333/PEACE-3 study demonstrated that enzalutamide plus radium-223 (Ra223) improved radiological progression-free survival (rPFS) compared to enzalutamide alone in patients wit...
HER2-positive gastroesophageal cancer: meaningful progress, unresolved biology [0.03%]
HER2阳性的胃食管癌：有意义的进步，未解决的生物学问题
H W M van Laarhoven,M F Bijlsma
H W M van Laarhoven
Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study [0.03%]
卡博替尼联合纳武利尤单抗和伊匹木单抗治疗既往未接受过治疗的晚期肾细胞癌：III 期 COSMIC-313 研究的最终结果及生物标志物分析
R J Motzer,L Albiges,S A Treviño Aguirre et al.
R J Motzer et al.
Background: Primary results from COSMIC-313 demonstrated significantly longer progression-free survival (PFS) with first-line cabozantinib plus nivolumab and ipilimumab versus placebo plus nivolumab and ipilimumab in pati...
Learning the Forest Before the Trees: Artificial Intelligence and Thymic Tumor Pathology [0.03%]
欲穷千里目，更上一层楼——人工智能与胸腺肿瘤病理学
Stefan Schulz,Sebastian Foersch
Stefan Schulz
Doubting T(h)OMAS: Has the era of precision oncology arrived in uterine leiomyosarcoma? [0.03%]
T(H)OMAS存疑：子宫平滑肌肉瘤的精准肿瘤学时代来临了吗？
E A De Jaeghere,A Dufresne,L Azarang et al.
E A De Jaeghere et al.
ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours [0.03%]
欧洲肿瘤内科学会系统治疗分期(EnLiST)共识体系：制定实体瘤治疗分期标准化规范框架
K S Saini,M Koopman,D Martins-Branco et al.
K S Saini et al.
Enumeration of lines of therapy (LoT) is critical across oncology for ensuring optimal patient care, establishing uniform eligibility for clinical trial enrolment, standardising use of real-world data (RWD), and pooling data for research pu...
PET/CT-Guided Management of Immune Checkpoint Blockade and Post-Treatment Multi-Modal Profiling in Long-Term Responders with Metastatic Lung Cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM) [0.03%]
国家网络基因组医学肺癌德国计划(nNGM)指导程序性死亡配体1检测及免疫检查点抑制剂治疗后多模式评估在晚期肺癌长期获益者中的应用
F Li,L Zhang
F Li